Spectroscopy Software Comparison: A Clinical Buyer's Checklist

If you are evaluating software to run spectroscopy-based diagnostics in a clinical setting, you are looking for a product category that barely exists. The spectroscopy industry has mature instrument software. The clinical informatics industry has mature laboratory information systems. Nothing connects the two. This guide gives you a structured framework for evaluating whatever options you find -- or for defining what you need to build.

We wrote this to be useful regardless of whether you ever talk to us. The checklist, scoring framework, and red flags apply to any vendor, any instrument, any clinical application. Print it out, bring it to vendor meetings, and score honestly.

The current landscape

Before you can evaluate options, you need to understand what exists. The spectroscopy clinical software market has three categories of players, each covering a different piece of the problem, and a conspicuous gap where those pieces should connect.

Instrument vendor software

Every major spectrometer ships with software that controls the instrument and processes spectral data. These are mature, powerful platforms -- and none of them address clinical workflow.

Bruker OPUS (v9.3) is the dominant platform for FTIR, NIR, and Raman measurement. It handles data acquisition, spectral processing, library searching, quantitative analysis, and evaluation workflows. OPUS supports cGMP and GLP compliance, validated methods, and comprehensive audit trails for pharmaceutical environments. What it does not do: HL7 or FHIR messaging, EHR connectivity, LIS interoperability, or patient-level tracking of any kind. OPUS is an analytical instrument tool. For details on its programmatic interfaces, see our Bruker OPUS integration guide.

Thermo Fisher OMNIC Paradigm (v2.6) is a tiered product controlling Thermo's FTIR instruments. It offers cloud-based collaboration through OMNIC Anywhere, multi-range spectral processing, and a modern UI. The same fundamental gap applies: no clinical data exchange, no patient-level tracking, no HL7/FHIR output.

Horiba LabSpec 6 handles Raman, photoluminescence, and cathodoluminescence with strong imaging capabilities. It offers GxP and 21 CFR Part 11 compliance through its ProtectionPlus module. Research and industrial tool. No clinical workflow.

Renishaw WiRE provides chemometrics and automation for Raman spectroscopy. Research and industrial tool with the most limited automation capabilities among the major vendors. No clinical workflow.

The key insight is this: every spectroscopy software package terminates at "spectrum analyzed." None of them continue to "result delivered to the clinician's EHR." This is not an oversight -- it is a structural feature of how the spectroscopy industry is organized. For the full analysis of why this gap exists, see our article on why instrument vendors do not build clinical software.

Laboratory information systems

On the other side of the gap sit the laboratory information systems (LIS) and laboratory information management systems (LIMS).

Orchard Harvest is a strong clinical LIS with good HL7 support, widely deployed in hospital reference labs. It receives results from analyzers and routes them to EHRs. It does not control instruments.

LabWare (approximately $6,900 per license with 15-20% annual maintenance) is an enterprise LIMS used across pharma, biotech, and clinical environments. It manages samples, tracks workflows, and integrates downstream. It does not control spectrometers.

STARLIMS is a Siemens-owned enterprise LIMS. Real-world implementations run $1.7-2.4M for medium-to-large deployments. Like LabWare, it is a downstream system.

Sunquest is a hospital-focused LIS from Clinisys. Strong in hospital lab workflows. Same story -- receives results, does not generate them from instruments.

Cloud-native challengers like QBench (approximately $375/user/month) and Scispot target smaller labs with lower-cost, modern platforms. They bring better UX and faster deployment but the same architectural limitation: they start at "sample received," not at "spectrum acquired."

The LIMS market is $3.5 billion as of 2024, projected to reach $7.2 billion by 2033 at 8.7% CAGR. It is a healthy, growing market. But LIMS and LIS are downstream systems. They track samples after results are generated. They do not control spectrometers, run classification models, or bridge the gap between a spectral measurement and a clinical result.

Custom development

When labs have needed to connect spectrometers to clinical workflows, they have historically hired development firms to build one-off solutions. Firms like Corwen Partners (acquired by Orchard in 2021) built custom integrations for individual laboratory deployments. The economics are painful:

• $250,000-500,000 per build
• 6-12 months of development
• Ongoing maintenance at $50,000-100,000 per year
• Each build is bespoke -- no reuse across customers, no shared improvements

For the full cost comparison between custom development and product-based approaches, see our build vs. buy analysis.

The gap

No product on the market today bridges spectroscopy instrument output through clinical classification to HL7/FHIR result delivery. No published comparison of spectroscopy software for clinical use exists -- because the category itself is nascent.

This is the gap that SpectraDx was built to fill: a clinical workflow platform purpose-built for spectroscopy-based diagnostics, connecting instrument control to EHR result delivery. But whether you evaluate SpectraDx or any other option, you need a rigorous framework. The rest of this article provides one.

The requirements checklist

What follows is the comprehensive checklist we recommend for evaluating any clinical spectroscopy software solution. For each item, we explain why it matters -- not just what to check, but what goes wrong when it is missing.

Instrument integration

Does it control your specific instrument model? If the software cannot directly control your spectrometer, your operators will switch between two applications for every measurement -- the instrument vendor's software for acquisition and the clinical software for everything else. This doubles training time, doubles error opportunities, and makes sub-90-second workflows impossible.

Does it support your instrument vendor's API/protocol? Bruker exposes DDE (and Named Pipes). Thermo Fisher uses COM automation. Horiba communicates over TCP/IP. Renishaw offers a limited SDK. Each vendor's integration path is different and each has undocumented quirks. Ask the vendor which specific protocol they use and whether they have deployed against your instrument model in production.

Can it handle multiple instruments from different vendors? Hospitals and QC labs rarely standardize on a single vendor. You may have a Bruker Alpha II for FTIR and a Horiba XploRA for Raman. If the software only supports one vendor, you need a second platform for the other -- and now you have two workflows, two training programs, and two sets of data to reconcile.

Does it support automated measurement sequences? Manual triggering -- where an operator clicks "Measure" for each sample -- does not scale past approximately 20 tests per day. Automated sequences (background check, sample measurement, QC verification, result delivery) are essential for clinical throughput.

Does it abstract the instrument layer? When you add a new instrument or replace an aging one, does the platform need a new adapter (a bounded change) or a new architecture (a rebuild)? Ask how they would support a new instrument vendor. If the answer involves more than writing a driver/adapter, the instrument layer is not abstracted.

Clinical workflow

Patient/MRN-based workflow, not sample-number-based? This is the single clearest indicator of whether software was designed for clinical use. Research labs track samples. Clinical labs track patients. If the software thinks in sample numbers and experiment files rather than medical record numbers and orders, it was not designed for clinical use. It will require workarounds for every clinical requirement.

Clinician-facing UI that does not require spectroscopy expertise? A nurse or medical technologist should be able to run a diagnostic test without training on OPUS or LabSpec. The interface should present "Run Test" and "Review Result," not "Configure Experiment Parameters" and "Select Apodization Function." For details on what a clinical-grade spectroscopy UI looks like, see our clinical workflow architecture article.

Result review and approval workflow? The two-person rule is standard in clinical laboratories: one person runs the test, another reviews and releases the result. This is a CLIA requirement for many test categories. If the software does not support review-and-release workflows with role-based access, your quality team will build a parallel paper-based system.

QC and calibration tracking? Clinical labs run daily quality control checks, calibration verifications, and proficiency testing. Results need Levey-Jennings charts, Westgard rule evaluation, and automatic lockout when QC fails. If the software does not track these, your quality team will build a parallel system in Excel. They will hate it. It will eventually fail an inspection.

The 90-second rule. From patient identification to result delivery, can the entire workflow complete in under 90 seconds? This is not an arbitrary target. At 90 seconds per test, one instrument can process approximately 40 tests per hour. At 5 minutes per test (which is common with manual instrument-software-EHR workflows), you get 12. The difference determines whether spectroscopy-based diagnostics are economically viable at your volume.

Interoperability

HL7v2 ORU^R01 output? This is the minimum requirement for U.S. hospital integration. The ORU^R01 message type carries observation results from analyzers to clinical systems. Every lab analyzer in the hospital sends ORU messages. If your spectroscopy platform cannot generate them, it cannot participate in the clinical data flow. For the technical details, see our HL7v2 spectroscopy integration guide.

FHIR R4 DiagnosticReport? CMS mandates FHIR API implementation by January 2027. Even if you launch with HL7v2 today, you will need FHIR R4 capability within the next 18 months. The DiagnosticReport resource is the FHIR equivalent of the ORU message. Start evaluating FHIR support now. See our FHIR R4 guide for spectroscopy.

Which EHR systems has it been tested against? Epic, Oracle Health (formerly Cerner), and MEDITECH each have different HL7 expectations, different interface engine configurations, and different certification requirements. "We support HL7" is a meaningless claim without specific EHR validation. Ask which EHR systems they have connected to in production, not in a demo environment.

LIS bidirectional interface? The best integration is bidirectional: receive orders from the LIS (so the operator does not manually enter patient information) and send results back. Unidirectional result-only interfaces are a minimum, but bidirectional interfaces eliminate data entry errors and reduce per-test time by 15-30 seconds. See our spectroscopy LIMS integration guide.

Standard data formats? Does the software import and export JCAMP-DX? Does it read vendor-native formats (Bruker OPUS binary, Thermo SPA/SPC, Horiba native)? If you cannot get your spectral data out in a standard format, you are locked in. For a comprehensive look at spectral data formats and why they matter, see our spectral data formats guide.

ML/AI integration

Can you plug in your own classification model? Your science team spent months or years training a classification model on your spectral data. The clinical software should run that model, not replace it with a proprietary one. Ask whether the platform supports ONNX, TensorFlow SavedModel, PyTorch, or scikit-learn model formats. If they only run their own models, your science team's work is wasted. See our AI spectral classification overview.

Does it support model versioning? When a result is audited six months later, which model version produced it? Which preprocessing pipeline was applied? Which training dataset was used? If the software does not track model versions alongside results, you cannot answer these questions -- and you will need to for any regulatory submission or quality investigation.

Confidence scoring and uncertainty quantification? A binary positive/negative result without a confidence score is not clinically useful. Clinicians need to know whether a classification is 99.2% confident or 51.3% confident. The difference changes clinical decision-making. For the technical details on implementing confidence scoring, see our confidence scoring guide.

Explainability features? SHAP values, LIME, spectral region attribution -- increasingly expected by FDA reviewers for AI/ML-based medical devices. The software should be able to show which spectral regions drove a classification decision. This is not a nice-to-have; it is becoming a regulatory expectation. See our explainable AI for spectroscopy article.

Configurable preprocessing pipeline? Baseline correction, normalization, ATR correction, smoothing, derivative calculation -- are these configurable per-method, or hardcoded? Different clinical applications require different preprocessing. A platform that hardcodes preprocessing will not work across multiple assay types. For the technical details, see our spectral preprocessing guide.

Compliance

21 CFR Part 11 audit trails? If you operate in a GMP environment -- pharmaceutical QC, contract testing, any FDA-regulated manufacturing -- electronic records and electronic signatures must comply with 21 CFR Part 11. This means complete audit trails (who did what, when, and why), electronic signature capability, and access controls. Instrument vendor software often has Part 11 modules, but the clinical workflow layer needs its own Part 11 compliance. If the clinical software does not have Part 11 capability, your entire workflow is non-compliant. See our 21 CFR Part 11 guide for spectroscopy software.

IEC 62304 lifecycle documentation? If the software is or will become a Software as a Medical Device (SaMD), IEC 62304 governs the software development lifecycle: requirements traceability, architecture documentation, unit testing, integration testing, risk management, and maintenance procedures. Ask to see the vendor's software lifecycle plan. If they do not have one, the software was not built with medical device intent, and you will not be able to use their documentation in your FDA submission. See our IEC 62304 guide.

HIPAA controls? If the software touches patient data -- and clinical spectroscopy software by definition does -- HIPAA applies. Encryption at rest and in transit, role-based access controls, audit logs, and breach notification capability are all required. This is table stakes, not a differentiator, but you would be surprised how many platforms built for research use lack basic HIPAA controls.

SaMD documentation transfer. If your spectroscopy-based diagnostic is or will become a regulated medical device, ask what documentation the vendor provides that transfers to your FDA submission. Design history file contributions? Verification and validation reports? Risk analysis? The answer determines how much regulatory work you inherit versus how much the vendor has already done. See our SaMD classification guide.

Scalability

Multi-site deployment? If you have -- or plan to have -- more than one lab location, ask how the platform handles multi-site deployment. Is it a separate installation per site, or a centralized platform with per-site configuration? Separate installations mean separate maintenance, separate upgrades, and separate data silos.

Centralized data and analytics? Can you see aggregate performance data across all sites from a single dashboard? Turnaround times, test volumes, QC trends, instrument utilization -- if these are only available per-site, you lose the operational visibility that multi-site deployment should provide.

Centralized method management? When you update a classification method or change a preprocessing parameter, can you deploy that change to all sites simultaneously? Or must you update each site individually? At two sites this is annoying. At ten sites it is a full-time job. At fifty sites it is unmanageable.

Commercial terms

Pricing model? License, SaaS, per-test, implementation fee -- there are many models, and the total cost of ownership varies dramatically. A $50,000 license with $10,000 annual maintenance looks cheaper than $3,000/month SaaS until you factor in server hardware, IT support, and upgrade cycles. Calculate total first-year cost and total five-year cost for a meaningful comparison.

Vendor lock-in risk? Can you export your spectral data, classification results, audit trails, and method configurations in standard formats? What happens to your data if you switch vendors? If the answer is "we will work with you on a transition plan" rather than "here is the export function," you are locked in.

What happens if the vendor goes away? Startups fail. Acquisitions happen. Ask about source code escrow agreements, data export capabilities, and contractual transition support. If your clinical workflow depends on a single vendor's platform and that vendor disappears, you need a contingency plan.

Red flags that should disqualify a vendor

In our experience working in the spectroscopy clinical software space, these are the warning signs that predict project failure. Any one of them should trigger deep due diligence. Two or more should end the conversation.

"We can build anything" without spectroscopy-specific experience. General-purpose development shops routinely underestimate the complexity of instrument integration by 3-5x. Interfacing with a spectrometer is not like calling a REST API. You are dealing with DDE connections, binary file formats, timing-sensitive acquisition sequences, and vendor-specific quirks that are not documented. A team that has never integrated a spectrometer will spend months on problems that an experienced team solves in weeks.

No existing instrument integrations. If the vendor has never connected to a spectrometer in production, you are paying for R&D, not buying a product. Every new instrument integration takes 3-6 months to build and validate. Multiply that by the number of instrument types you need.

No HL7/FHIR experience. HL7 integration is the most expensive part of clinical software to get wrong. The specification is ambiguous. Every receiving system interprets it differently. A developer who has never built an HL7 interface will spend months debugging message formatting, segment ordering, and acknowledgment handling. Ask for the names of hospital EHR systems they have connected to. If they cannot name any, they have not done it.

No regulatory documentation. If they cannot show you their IEC 62304 software lifecycle documentation, their 21 CFR Part 11 audit trail implementation, or their design history file, they do not have these things. Regulatory compliance is not something you retrofit onto a finished product. It is baked into the development process from day one, or it does not exist.

Per-instrument pricing that penalizes growth. If the cost model charges per-instrument with no volume discount, your cost scales linearly (or worse) with growth. At five instruments, a $10,000/instrument/year license is $50,000. At fifty instruments across ten sites, it is $500,000 -- and you have not gained any economies of scale. Your cost should scale sub-linearly with growth.

No reference customers in spectroscopy or clinical labs. Ask for references. Specifically ask for references in spectroscopy applications and in clinical laboratory environments. Call those references. Ask about implementation timeline, support responsiveness, and what surprised them after deployment. If the vendor cannot provide references, you are the reference customer -- and you will pay for that privilege in time and frustration.

"We will figure out HL7 later." This is the single most dangerous statement a vendor can make. HL7 integration is not a feature you bolt on at the end. It drives architectural decisions from day one: data models, result encoding, patient context threading, message queuing, error handling, and retry logic. A platform built without HL7 in mind will require significant rearchitecting to add it later.

Demo shows only the happy path. Every vendor demo shows a perfect measurement on a perfect sample producing a perfect result. That is not the test. Ask what happens when:

• The instrument times out during acquisition
• The spectrum quality score falls below the acceptable threshold
• The patient MRN does not match any order in the LIS
• The network connection to the EHR drops during result transmission
• A QC check fails mid-shift
• Two operators try to use the same instrument simultaneously

If the vendor cannot demonstrate or clearly explain error handling for these scenarios, they have not thought about them. In clinical environments, error handling is the product.

Evaluation framework: weighted scoring matrix

A checklist tells you what to look for. A scoring matrix tells you how to compare. Here is the framework we recommend.

Base scoring matrix

Rate each vendor on a 1-10 scale for each category. Multiply by the weight. Sum for a weighted total.

This base weighting reflects a general-purpose clinical spectroscopy deployment. But the right weights depend on who you are.

Weight adjustment by use case

For a diagnostic startup building a spectroscopy-based IVD:

The startup weighting front-loads instrument integration and clinical workflow because these are the hardest to change later. A startup that picks software with weak instrument control will spend months on workarounds. A startup that picks software with poor clinical workflow will struggle to demonstrate usability in its regulatory submission.

For a pharma QC lab deploying spectroscopy for raw material identification or product release:

The pharma weighting prioritizes compliance because a GMP audit finding against your software is a production shutdown risk. Scalability ranks higher because pharma companies deploy across multiple manufacturing sites and need centralized control.

For a hospital clinical lab adding spectroscopy-based diagnostics to their test menu:

The hospital weighting front-loads interoperability because a diagnostic test that does not integrate with the EHR will not be adopted. Hospital labs are integration-centric environments. Every analyzer, every LIS, every reference lab connection runs through the integration engine. A spectroscopy platform that cannot participate in that ecosystem is dead on arrival.

How to customize for your situation

The three profiles above are starting points. Adjust them based on your specific context:

• If you are in a highly regulated environment (clinical trials, FDA-cleared diagnostics), increase Compliance weight by 5-10 points and decrease Commercial Terms and Scalability proportionally.
• If you are deploying a novel assay with active model development, increase ML/AI Integration by 5-10 points.
• If you are in a multi-site health system or contract lab network, increase Scalability by 5-10 points.
• If you are a single-site operation with stable, proven assays, decrease ML/AI and Scalability and redistribute to Clinical Workflow and Interoperability.

The weights should reflect your deployment reality, not an abstract ideal.

Scoring guidance

To make scores comparable across evaluators, use this rubric:

• 1-2: Capability does not exist. Vendor acknowledges the gap.
• 3-4: Capability is planned or in early development. No production deployment.
• 5-6: Capability exists but is limited. Workarounds required for your use case.
• 7-8: Capability is solid. Meets most requirements with minor gaps.
• 9-10: Capability is exceptional. Exceeds requirements. Production-validated.

Be disciplined about this. A vendor that says "we support HL7" but has never connected to an EHR in production is a 3, not a 7. A vendor with three production EHR integrations running daily is an 8. Score based on evidence, not promises.

Running the evaluation

With the checklist and scoring framework in hand, here is the practical process for running an evaluation.

Step 1: Define your requirements

Before you talk to any vendor, fill out the checklist for your own environment. Which instruments do you have? Which EHR system? What regulatory framework applies? What is your expected test volume? How many sites? This becomes your evaluation baseline.

Step 2: Set your weights

Choose the weight profile that best matches your organization (diagnostic startup, pharma QC, hospital lab) and customize it. Document why you chose each weight. This prevents the evaluation from drifting toward whichever vendor demos best.

Step 3: Request structured demos

Do not let vendors run their standard demo. Give them a script based on your checklist. Ask them to demonstrate:

1. Instrument control with your specific instrument model (or a close equivalent)
2. A complete workflow from patient identification to result delivery
3. HL7/FHIR message generation (show the raw message, not just "it integrates")
4. Model import and versioning (bring your own model if possible)
5. Audit trail and compliance features
6. Error handling scenarios (instrument timeout, low-quality spectrum, network failure)

Score each category during the demo, not after. Memory is unreliable.

Step 4: Check references

Ask each vendor for three reference customers. Call them. Ask:

• How long did implementation take versus the original estimate?
• What was the biggest surprise after deployment?
• How responsive is support when something breaks at 2 AM?
• Would you choose this vendor again?

If a vendor cannot provide references, that is a score of 1 in every category.

Step 5: Calculate and compare

Multiply each category score by its weight. Sum for each vendor. The highest weighted total is your leading candidate -- but the score is a starting point for discussion, not a final answer. Look at category-level scores to identify risks. A vendor that scores 9 overall but 3 on Compliance is a risky choice for a regulated environment, regardless of the total.

A note on timing

The spectroscopy clinical software market is evolving rapidly. New entrants are emerging. Instrument vendors are beginning to acknowledge the clinical gap. The LIMS market is consolidating. What is true today about available options may not be true in twelve months.

What will not change is the evaluation framework. The categories, the questions, and the red flags are structural. Instrument integration, clinical workflow, interoperability, ML support, compliance, scalability, and commercial terms will matter for any clinical spectroscopy deployment, regardless of when you evaluate or which vendors are available.

Use this checklist now. Update your scores as the market evolves. And when you find a vendor that scores well across all categories -- or when you decide to build -- you will know exactly what you need and why.